These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38750345)

  • 1. Access to melanoma drugs in Spain: a cross-sectional survey.
    Gonzalez-Cao M; Puertolas T; Manzano JL; Maldonado C; Yelamos O; Berciano-Guerrero MÁ; Cerezuela P; Martin-Liberal J; Muñoz-Couselo E; Espinosa E; Drozdowskyj A; Berrocal A; Soria A; Marquez-Rodas I; Martin-Algarra S; Quindos M; Puig S;
    Clin Transl Oncol; 2024 May; ():. PubMed ID: 38750345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis.
    Cerezuela-Fuentes P; Gonzalez-Cao M; Puertolas T; Manzano JL; Maldonado C; Yelamos O; Berciano-Guerrero MA; Martin-Liberal J; Muñoz-Couselo E; Espinosa E; Drozdowskyj A; Berrocal A; Soria A; Marquez-Rodas I; Martin-Algarra S; Quindos M; Puig S;
    Clin Transl Oncol; 2024 Jul; ():. PubMed ID: 38951438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel adjuvant options for cutaneous melanoma.
    Dimitriou F; Long GV; Menzies AM
    Ann Oncol; 2021 Jul; 32(7):854-865. PubMed ID: 33771664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of stage IIB-IV melanoma patients: nationwide data from Norway.
    Winge-Main A; Robsahm TE; Nyakas M; Festervoll G; Torkilseng E; Thybo S; Pati S; Carroll R
    Future Oncol; 2023 Jan; 19(3):205-215. PubMed ID: 36974621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain.
    Rodríguez-Lescure A; de la Peña FA; Aranda E; Calvo A; Felip E; Garrido P; Vera R
    Clin Transl Oncol; 2020 Dec; 22(12):2253-2263. PubMed ID: 32533318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
    Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J
    Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis.
    Christofyllakis K; Pföhler C; Bewarder M; Müller CSL; Thurner L; Rixecker T; Vogt T; Stilgenbauer S; Yordanova K; Kaddu-Mulindwa D
    Front Oncol; 2020; 10():637161. PubMed ID: 33680957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N; Bagust A; Boland A; Beale S; Richardson M; Krishan A; Stainthorpe A; Abdulla A; Kotas E; Banks L; Payne M
    Pharmacoeconomics; 2017 Oct; 35(10):1035-1046. PubMed ID: 28316007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
    Eggermont AMM; Dummer R
    Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
    Larkin J; Weber J; Del Vecchio M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Di Giacomo AM; Middleton MR; De la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Long GV; Lobo M; Askelson M; Ascierto PA; Mandalá M
    Eur J Cancer; 2022 Sep; 173():285-296. PubMed ID: 35964471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
    Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
    Weber J; Mandala M; Del Vecchio M; Gogas HJ; Arance AM; Cowey CL; Dalle S; Schenker M; Chiarion-Sileni V; Marquez-Rodas I; Grob JJ; Butler MO; Middleton MR; Maio M; Atkinson V; Queirolo P; Gonzalez R; Kudchadkar RR; Smylie M; Meyer N; Mortier L; Atkins MB; Long GV; Bhatia S; Lebbé C; Rutkowski P; Yokota K; Yamazaki N; Kim TM; de Pril V; Sabater J; Qureshi A; Larkin J; Ascierto PA;
    N Engl J Med; 2017 Nov; 377(19):1824-1835. PubMed ID: 28891423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Validation inspection of prescription drugs in Spain: current situation from a health professional perspective after its introduction in electronic form].
    Orozco D; Basora J; García L; Paz S; Lizan L
    Aten Primaria; 2013 Feb; 45(2):74-81. PubMed ID: 23149119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparities in Receipt of Adjuvant Immunotherapy among Stage III Melanoma Patients.
    Mulligan KM; Kakish H; Pawar O; Ahmed FA; Elshami M; Rothermel LD; Bordeaux JS; Sheng IY; Mangla A; Hoehn RS
    Am J Clin Oncol; 2024 Jun; ():. PubMed ID: 38937882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant vemurafenib in resected, BRAF
    Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
    Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Programs of early detection of breast cancer and access of mammography in Spain].
    Luengo S; Azcona B; Lázaro P; Madero R
    Med Clin (Barc); 1997 May; 108(20):761-6. PubMed ID: 9265079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Characteristics of communication systems of suspected occupational disease in the Autonomous Communities, Spain].
    García Gómez M; Urbaneja Arrúe F; García López V; Estaban Buedo V; Rodríguez Suárez V; Miralles Martínez-Portillo L; González García I; Egea Garcia J; Corraliza Infanzon E; Ramírez Salvador L; Briz Blázquez S; Armengol Rosell R; Cisnal Gredilla JM; Correa Rodríguez JF; Coto Fernández JC; Díaz Peral MR; Elvira Espinosa M; Fernández Fernández I; García-Ramos Alonso E; Martínez Arguisuelas N; Rivas Pérez AI
    Rev Esp Salud Publica; 2017 Mar; 91():. PubMed ID: 28301455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
    Ascierto PA; Di Giacomo AM; Chiarion Sileni V; Queirolo P; Spagnolo F; De Galitiis F; Cognetti F; Mandalà M; Guidoboni M; Rinaldi G; Depenni R; Consoli F; Troiani T; Guida M; Marconcini R; Ferrucci PF; Strippoli S; Fava P; Merelli B; Simeone E; Di Guardo L; Giannarelli D; Maio M; Quaglino P; Del Vecchio M
    Eur J Cancer; 2023 Sep; 191():113246. PubMed ID: 37549531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system.
    Fujisawa Y; Yoshikawa S; Minagawa A; Takenouchi T; Yokota K; Uchi H; Noma N; Nakamura Y; Asai J; Kato J; Fujiwara S; Fukushima S; Uehara J; Hoashi T; Kaji T; Fujimura T; Namikawa K; Yoshioka M; Murata N; Ogata D; Matsuyama K; Hatta N; Shibayama Y; Fujiyama T; Ishikawa M; Yamada D; Kishi A; Nakamura Y; Shimiauchi T; Fujii K; Fujimoto M; Ihn H; Katoh N
    J Dermatol Sci; 2019 May; 94(2):284-289. PubMed ID: 31023613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.